Скачать с ютуб Genetic Testing and Parp Inhibitors Explained | Celestial Higano, MD & Mark Moyad, MD, MPH | PCRI в хорошем качестве

Genetic Testing and Parp Inhibitors Explained | Celestial Higano, MD & Mark Moyad, MD, MPH | PCRI

Watch the entire 2021 Mid-Year Update here:    • 2021 Moyad + Scholz Mid-Year Update |...   Mark Moyad, MD, MPH, asks Celestia Higano, MD, about PARP inhibitors and genetic testing (both germline and somatic). Olaparib (Lynparza) and rucaparib (Rubraca) are two PARP inhibitors that were recently FDA approved to treat metastatic prostate cancer in men with BRCA1 or BRCA2 mutations. "Germline" genetic testing concerns the genes that a person was born with and somatic genetic testing looks at the genetic makeup of a prostate cancer tumor. Don’t know your stage? Take the quiz: Visit http://www.prostatecancerstaging.org To learn more about prostate cancer visit http://www.pcri.org Who we are: The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors. The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs. #CelestiaHiganoMD #MarkMoyadMD #ProstateCancer